Accordingly, mutations in tumor cells include the EGFR, erythroblastic oncogene B2 (HER2/ERBB2), FGFR2, platelet-derived growth factor receptor (PDGFR), transforming growth factor beta receptor 2 (TGFβR2), MET oncogene, KIT proto-oncogene, Ras oncogene, Raf proto-oncogene, phosphatidylinositol 3-kinase cancer mutation (PI3KCA), and/or the phosphatase and tensin homolog deleted on chromosome ten (PTEN) genes [54]. This evidence concerns the gene TGFBR2 and neoplasm.